

MEDCHI, THE MARYLAND STATE MEDICAL SOCIETY
HOUSE OF DELEGATES

Resolution 23-14

INTRODUCED BY: Baltimore County Medical Society

SUBJECT: Transparency of Pharmaceutical Manufacture

1 Whereas, generic pharmaceuticals fill 84% of prescriptions dispensed in the U.S., but account for just 27% of the
2 total drug spending according to the Generic Pharmaceutical Association; and
3
4 Whereas, 80% of active pharmaceutical ingredients are imported into the U.S. and 40% of finished drugs according
5 to the FDA, though there is no good information on the percent of finished generic drugs imported; and
6
7 Whereas, even U.S. headquartered generics manufacturers are rushing to expand overseas manufacturing,
8 especially to India; and
9
10 Whereas, there have been a number of voluntary recalls and a lack of close monitoring by the FDA or by the
11 monitoring agencies in some foreign countries, especially India and China; therefore be it
12
13 Resolved, that MedChi ask our AMA to study quality control and transparency of pharmaceutical manufacturing
14 and advocate for improved monitoring of manufacturing and finished product in countries supplying drugs to the
15 U.S.; and be it further
16
17 Resolved, that MedChi ask our AMA to advocate that until such time as U.S. monitoring and foreign manufacturing
18 is deemed adequate, the source country of the active pharmaceutical ingredients and of the manufacture of the
19 finished drugs shall be included on the labels of all medications available to American consumers.
20
21
22 As adopted by the House of Delegates at its meeting on September 27, 2014.
